Highlights Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Real-time Estimate Cboe BZX Other stock markets 12:25:43 2024-05-01 pm EDT			5-day change	1st Jan Change
3.88 ^USD	-0.51%		+8.56%	-82.41%

Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement	Feb. 20	CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data	Feb. 08	MT
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients	Feb. 07	CI
Reverse Split: 1 of 80	Jan. 02	FA
Tenax Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Tenax Therapeutics, Inc. Announces FDA Clearance of IND for TNX-103 for the Treatment of Pulmonary Hypertension with Heart Failure	Nov. 13	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Tenax Therapeutics Issues U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	23-07-19	CI
Tenax Therapeutics, Inc. Receives a Notice of Allowance from the United States Patent and Trademark Office for its Patent Application	23-05-31	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Tenax Receives Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)	23-02-01	CI
Reverse Split: 1 of 20	23-01-04	FA
Tenax Therapeutics to Effect 1-for-20 Reverse Stock Split	23-01-04	MT
Tenax Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Tenax Therapeutics, Inc. Announces the Presentation of Positive Data from a Study of PH-HFpEF Patients Being Treated with Oral Levosimendan	22-10-10	CI
Tenax Therapeutics Says It Is Evaluating Alternatives to Maximize Shareholder Value; Shares Rise	22-09-15	MT
Tenax Therapeutics Inc. Announces the Evaluation of Strategic Alternatives	22-09-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Highlights

Filters